Helius Medical Technologies, Inc. is a neurotech company focused on addressing neurologic deficits with its orally applied technology platform, which enhances the brain's compensatory mechanisms. Co. develops, licenses, or acquires non-implantable technologies aimed at reducing symptoms of neurological diseases or trauma. Its key product, the Portable Neuromodulation Stimulator (PoNS), is a non-implantable device that delivers mild electrical stimulation to the tongue, aiding in the treatment of gait and chronic balance deficits. PoNS Therapy, used alongside supervised therapeutic exercises, is prescribed for patients aged 22 and over. We show 31 historical shares outstanding datapoints in our coverage of HSDT's shares outstanding history.
Understanding the changing numbers of HSDT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like HSDT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching HSDT by allowing them to research HSDT shares outstanding history
as well as any other stock in our coverage universe. |
Free HSDT Email Alerts:
Video: Shares Outstanding Importance
